Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 22;30(1):652.
doi: 10.1186/s40001-025-02801-2.

Impact of liraglutide on albumin-to-creatinine ratio in type 2 diabetes mellitus: a meta-analysis

Feng Wang  1 , Guangzhong Xu  1 , Wei Feng  2 , Gengbao Qu  1 , Pengyu Li  1 , Kai Li  3
Affiliations
Review

Impact of liraglutide on albumin-to-creatinine ratio in type 2 diabetes mellitus: a meta-analysis

Feng Wang et al. Eur J Med Res. .

Abstract

Aims: Emerging evidence suggested that liraglutide possessed the potential to improve the albumin-to-creatinine ratio (ACR) in patients with type 2 diabetes mellitus (T2DM). This study aimed to ascertain the impact of liraglutide on ACR in T2DM.

Methods: PubMed, Embase, the Cochrane Library, WanFang and CNKI were searched for randomized controlled trials (RCTs) from inception to November 30, 2024 (PROSPERO: CRD52025336785). The data were pooled using fixed- or random-effects models based on the heterogeneity. Sensitivity analyses and publication bias assessments were performed.

Results: Seven RCTs involving 473 participants were included. Liraglutide significantly reduced ACR (WMD: - 11.76 mg/g, 95% CI, - 21.71 to - 1.81, I2 = 75%, P = 0.02) compared to controls (placebo or active drugs). Subgroup analysis revealed significant ACR reductions in patients with HbA1c > 8.0%, follow-up > 12 weeks, and age < 60 years. Meta regression indicated that heterogeneity was not influenced by sample size, HbA1c, baseline ACR, treatment duration, or liraglutide dosage (P = 0.92; 95% CI, - 322.34 to 340.66). The results were stable based in sensitivity analysis, and no publication bias was detected (Begg's P = 0.46; Egger's P = 0.57).

Conclusions: Liraglutide significantly reduced ACR in T2DM, particularly in patients with poor glycemic control, longer treatment duration, and younger age. Future studies with extended follow-up are needed to confirm its renoprotective benefits.

Keywords: Albumin-to-creatinine ratio; Liraglutide; Randomized controlled trials; Type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flow chart of the number of studies identified in the meta-analysis
Fig. 2
Fig. 2
Assessment of bias in the included studies according to Cochrane criteria
Fig. 3
Fig. 3
Forest plot of the impact of liraglutide versus comparators on ACR in T2DM
Fig. 4
Fig. 4
Leave-one-out sensitivity test for the effect of liraglutide on ACR in T2DM
Fig. 5
Fig. 5
Assessment of publication bias in the meta-analysis estimating the impact of liraglutide on ACR
See this image and copyright information in PMC

References

    1. Rayego-Mateos S, Rodrigues-Diez RR, Fernandez-Fernandez B, Mora-Fernández C, Marchant V, Donate-Correa J, Navarro-González JF, Ortiz A, Ruiz-Ortega M. Targeting inflammation to treat diabetic kidney disease: the road to 2030. Kidney Int. 2023;103:282–96. - PubMed
    1. MacIsaac RJ, Trevella P, Ekinci EI. Glucagon-like peptide-1 receptor agonists and kidney outcomes. J Diabetes. 2024;16: e13609. - PMC - PubMed
    1. Shamim MA, Patil AN, Amin U, Roy T, Tiwari K, Husain N, Kumar J, Chenchula S, Rao P, Ganesh V, et al. Glucagon-like peptide-1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity—a systematic review and network meta-analysis. Diabetes Obes Metab. 2024;26:4302–17. - PubMed
    1. Mann JFE, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T, von Scholten BJ, Poulter NR. Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease. Circulation. 2018;138:2908–18. - PMC - PubMed
    1. Wang N, Zhang C. Recent advances in the management of diabetic kidney disease: slowing progression. Int J Mol Sci 2024;25:3086-3092. - PMC - PubMed

MeSH terms

LinkOut - more resources